Significant advances have been made in the development of new treatments for blood cancer patients. New targeted drugs are available and are starting to replace harsher, chemotherapy-based treatments. Nevertheless, these advanced new drugs are only available for a portion of patients who have specific genomic changes in their cancer. In addition, patients often become resistant to the new therapies as their cancer evolves to escape the drug effects. Thus, there is still a major need to identify novel, therapeutic strategies. In these studies, we will investigate the activity of these novel drugs for acute leukemia and myelodysplastic syndrome. We will characterize drug responsive and resistant patient groups using molecular and clinical information. Based on this information we can design tests that easily identify responding and non-responding patients. In addition, the results can be used for the design and proposal of early phase clinical investigations.

2023

2027